Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 4,116 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $13.35, for a total transaction of $54,948.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Craig A. Wheeler also recently made the following trade(s):

  • On Friday, September 1st, Craig A. Wheeler sold 20,367 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $17.00, for a total transaction of $346,239.00.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded up $0.10 during trading hours on Friday, hitting $13.80. 166,470 shares of the stock were exchanged, compared to its average volume of 767,625. Momenta Pharmaceuticals, Inc. has a 1 year low of $11.85 and a 1 year high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.03. The firm had revenue of $24.09 million for the quarter, compared to analyst estimates of $29.58 million. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The business’s revenue for the quarter was down 17.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.26) EPS. equities research analysts expect that Momenta Pharmaceuticals, Inc. will post -1.16 earnings per share for the current fiscal year.

Several analysts have issued reports on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $26.00 target price on shares of Momenta Pharmaceuticals in a research note on Thursday, August 3rd. J P Morgan Chase & Co reiterated a “hold” rating and issued a $14.00 target price on shares of Momenta Pharmaceuticals in a research note on Thursday, October 5th. BidaskClub cut shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Goldman Sachs Group Inc assumed coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, September 28th. They issued a “neutral” rating and a $18.00 target price on the stock. Finally, ValuEngine cut shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Three research analysts have rated the stock with a sell rating and nine have given a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $15.00.

Several large investors have recently modified their holdings of MNTA. Ameritas Investment Partners Inc. increased its holdings in shares of Momenta Pharmaceuticals by 14.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock worth $109,000 after buying an additional 834 shares during the last quarter. Tortoise Investment Management LLC bought a new position in shares of Momenta Pharmaceuticals in the 2nd quarter worth $114,000. Pinebridge Investments L.P. increased its holdings in shares of Momenta Pharmaceuticals by 4.3% in the 2nd quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock worth $149,000 after buying an additional 363 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in shares of Momenta Pharmaceuticals by 84.6% in the 2nd quarter. State of Alaska Department of Revenue now owns 13,184 shares of the biotechnology company’s stock worth $222,000 after buying an additional 6,044 shares during the last quarter. Finally, Profund Advisors LLC increased its holdings in shares of Momenta Pharmaceuticals by 13.1% in the 2nd quarter. Profund Advisors LLC now owns 13,172 shares of the biotechnology company’s stock worth $223,000 after buying an additional 1,530 shares during the last quarter. 93.68% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/craig-a-wheeler-sells-4116-shares-of-momenta-pharmaceuticals-inc-mnta-stock/1724749.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.